Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations and Corporate Communications Fred Vogt - Interim President and Chief Executive Officer Igor Bilinsky - Chief Operating Officer Jim Ziegler - Executive Vice President, Commercial Friedrich Finckenstein - Chief Medical Officer Jean-Marc Bellemin - Chief Financial Officer Raj Puri - Executive Vice President, Regulatory Strateg ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from __________ to __________ Commission file number: 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Del ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President of Investor Relations and Corporate Communications Frederick Vogt - Interim President and Chief Executive Officer Jean-Marc Bellemin - Chief Financial Officer Igor Bilinsky - Chief Operating Officer James Ziegler - Executive Vice President, Commercial Friedrich Finckenstein - Chief Medical Officer Madan Jagasia - Executive Vice President, Medica ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 75-3254381 825 Industrial Road, Suite 400, San Carlos, CA 94070 (Address of principal executive offices and zip code) (650) 260-7120 (Registrant's telephone number, includi ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor & Public Relations & Corporate Communications Fred Vogt - Interim President & Chief Executive Officer Igor Bilinsky - Chief Operating Officer Jim Ziegler - Executive Vice President, Commercial Friedrich Finckenstein - Chief Medical Officer Jean-Marc Bellemin - Chief Financial Officer Conference Call Participants Peter Lawson - Barclays ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) (State or other jurisdiction of (I.R ...

1 I OVANCE 1 Corporate Overview May 2022 © 2022, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, other than statements of historical fact, are forward-looking statements an ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2022 Results Conference Call May 5, 2022 4:30 PM ET Company Participants Sara Pellegrino - Vice President, Investor and Public Relations Dr. Fred Vogt - Interim President and Chief Executive Officer Dr. Igor Bilinsky - Chief Operating Officer Jim Ziegler - Senior Vice President, Commercial Dr. Friedrich Finckenstein - Chief Medical Officer Dr. Madan Jagasia - Senior Vice President, Medical Affairs Jean-Marc Bellemin - Chief Financial Officer Dr. Raj Puri - Exec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) (State or other jurisdiction of (I. ...

1 I OVANCE 1 Corporate Overview March 2022 © 2022, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, other than statements of historical fact, are forward-looking statements ...